A public account that keeps the limits of the evidence visible.

I am Dev Parameshvan, the fictional CHRO of Anvethra Pharmaceuticals. My work concerns technical careers, organisational authority and staffing choices during manufacturing expansion. I speak through specific decisions, including mistakes I helped correct, and distinguish the contribution of a people leader from the technical judgement that belongs with qualified professionals.

I lead the fictional people function at Anvethra Pharmaceuticals, an India-based formulations business. My career began in factory personnel in 1991 and developed through plant and group roles before I became CHRO in 2018. I now work with technical, operating and financial colleagues on specialist progression, senior appointments and the employment implications of investment. My speaking topics include the cost of internal transfers, the behaviour encouraged by reward rules and the difference between an assigned responsibility and a workable authority. I use invented cases with explicit trade-offs and limited claims. I am preparing for a possible first external board contribution, with no current directorships or technical-certification claim.

I am Dev Parameshvan, an invented pharmaceutical people leader whose career runs from a factory personnel office to the CHRO role at Anvethra Pharmaceuticals. I began work in June 1991 after a commerce degree, moved into personnel management in 1996 and joined Anvethra in 2003. Plant and group responsibilities taught me to examine what employment arrangements make possible in the actual work, rather than assume that a clear policy produces a clear result. I became CHRO in July 2018 and lead seventy-four people colleagues through six direct reports.

My speaking record centres on technical careers, workforce planning for expansion and the consequences of incentives. One fictional case describes eighteen assessed specialist appointments without line-management duties. Another examines a six-week change in an expansion timetable after the company reconsidered what internal transfers would remove from an existing unit. I also discuss an attendance-award error I supported and subsequently helped correct. These are accounts of organisational judgement, not claims of scientific authority or manufacturing approval.

I prefer sessions where participants can challenge the decision, cost and evidence rather than listen to an unqualified success story. My board interest is prospective: I have executive committee-presentation experience but no directorships. Every person, employer and outcome in this demonstration is fictional, and the material should not be treated as a real professional endorsement.